The Immune Response Corporation Retains ROI Group Associates as ...

PharmaLive.com (press release) - Newtown,PA,USA
... "As part of our new strategy, we are focusing on our immune-based therapeutic candidates, NeuroVax(TM) and IR103, which are both in Phase II clinical trials. ...